

---

## Contents

### CHAPTER 1

#### **Genetic Changes and Their Influence on Structure and Function of the Eye in Glaucoma**

ERNST R. TAMM

1.1	Introduction .....	1
1.2	Glaucoma in Developmental Disorders .....	2
1.2.1	Development of the Ocular Mesenchyme in the Anterior Eye ...	2
1.2.2	Axenfeld-Rieger's Syndrome, Peters' Anomaly and Anterior Segment Dysgenesis .....	4
1.2.3	Aniridia .....	9
1.2.4	Primary Congenital Glaucoma .....	11
1.2.5	Nail-Patella Syndrome .....	13
1.3	Genes and Primary Open-Angle Glaucoma (POAG).....	13
1.3.1	Loci for POAG .....	14
1.3.2	Myocilin .....	15
1.3.3	Optineurin .....	19
1.4	Genes and Pigmentary Glaucoma ..	21
	References .....	21

### CHAPTER 2

#### **Neuroprotection in Glaucoma**

LEONARD A. LEVIN

2.1	Introduction .....	29
2.1.1	Basics .....	29
2.1.2	Rationale for Neuroprotection in Glaucoma .....	30
2.1.3	Necessary Steps for Neuroprotection ..	31
2.2	Preclinical Evidence for Neuroprotection in Glaucoma .....	31
2.2.1	NMDA Receptor Antagonists .....	31

2.2.2	$\alpha$ 2-Adrenergic Receptor Agonists ..	32
2.2.3	$\beta$ 1-Adrenergic Receptor Antagonists ..	32
2.2.4	Nitric Oxide Synthase Antagonists ..	33
2.2.5	Reactive Oxygen Species Scavengers and Lipid Peroxidation Inhibitors .....	33
2.2.6	Neurotrophic Factors .....	33
2.2.7	Vaccination .....	34
2.3	Clinical Experience with the Described Substances .....	34
2.4	Current Clinical Practice/Recommendations .....	36
	References .....	36

### CHAPTER 3

#### **Screening for Glaucoma**

EVE J. HIGGINBOTHAM

3.1	Introduction .....	39
3.2	Why Screen for Glaucoma? .....	40
3.2.1	The Burden of Untreated Disease ..	40
3.2.2	The Importance of Early Detection .....	41
3.2.3	The Lack of Knowledge Regarding Glaucoma in the Lay Community ..	41
3.3	Current Screening Practices and Experience .....	42
3.4	Specific Screening Tests .....	43
3.4.1	Rationale for a Risk Factor Questionnaire .....	43
3.4.2	Frequency-Doubling Technology ...	43
3.4.3	Scanning Laser Polarimetry .....	44
3.5	The Promise of Teleophthalmology .....	46
3.6	The Cost-Effectiveness of Screening for Glaucoma .....	46
	References .....	49

## CHAPTER 4

**Semi-automated Kinetic Perimetry  
for Assessment of Advanced Glaucomatous  
Visual Field Loss**ULRICH SCHIEFER, K. NOWOMIEJSKA,  
J. PAETZOLD

4.1	Introduction .....	51
4.2	Methods/Methodological Aspects ..	52
4.3	Assessment and Definition of "Local Kinetic Threshold" and Local Scatter .....	57
4.4	Assessment and Importance of Individual Reaction Time .....	57
4.5	Selection of Optimum Target Angular Velocity .....	58
4.6	Age-Related Normative Values .....	58
4.7	Comparability of SKP Results with Those of Conventional Manual Kinetic Perimetry Using the GOLDMANN Instrument .....	58
4.8	Evaluation of Individual Functional Impairment/Expert Opinion .....	59
4.9	Training, Education and Learning ..	59
4.10	Outlook .....	59
	References .....	60

## CHAPTER 5

**Optic Nerve Imaging: Recent Advances**LINDA M. ZANGWILL, FELIPE A. MEDEIROS,  
CHRISTOPHER BOWD, ROBERT N. WEINREB

5.1	Introduction .....	63
5.1.1	Background .....	63
5.1.2	Image Quality .....	65
5.1.3	Reproducibility .....	66
5.1.4	Detecting Glaucoma .....	66
5.1.5	Association Between Structure and Function .....	66
5.1.6	Detecting Change Over Time .....	66
5.2	Confocal Scanning Laser Ophthalmoscopy .....	67
5.2.1	Background .....	67
5.2.2	Image Quality .....	71
5.2.3	Reproducibility .....	71
5.2.4	Detecting Early to Moderate Glaucoma .....	72
5.2.5	Relationship Between Structure and Function .....	72

5.2.6	Detecting Change Over Time .....	72
5.2.7	Strengths and Limitations .....	74
5.3	Scanning Laser Polarimetry .....	74
5.3.1	Background .....	74
5.3.2	Image Quality .....	76
5.3.3	Reproducibility .....	76
5.3.4	Detecting Early to Moderate Glaucoma .....	76
5.3.5	Relationship Between Structure and Function .....	78
5.3.6	Detecting Change Over Time .....	78
5.3.7	Strengths and Limitations .....	78
5.4	Optical Coherence Tomography ...	79
5.4.1	Background .....	79
5.4.2	Image Quality .....	81
5.4.3	Reproducibility .....	82
5.4.4	Detecting Early to Moderate Glaucoma .....	82
5.4.5	Relationship Between Structure and Function .....	83
5.4.6	Detection of Longitudinal Change over Time .....	84
5.4.7	Strengths and Limitations .....	85
5.5	Scanning Retinal Thickness Analyzer .....	85
5.5.1	Background .....	85
5.5.2	Image Quality .....	86
5.5.3	Reproducibility .....	86
5.5.4	Discriminating Between Healthy Eyes and Eyes with Early to Moderate Glaucoma .....	86
5.5.5	Relationship Between Structure and Function .....	86
5.5.6	Detecting Change Over Time .....	87
5.5.7	Strengths and Limitations .....	87
5.6	Conclusions .....	87
	References .....	88

## CHAPTER 6

**New Concepts in the Diagnosis  
of Angle-Closure Glaucoma:  
The Role of Ultrasound Biomicroscopy**CELSO TELLO, JEFFREY M. LIEBMANN,  
ROBERT RITCH

6.1	Introduction .....	93
6.2	Ultrasound Biomicroscopy .....	94
6.3	The Normal Eye .....	96

6.4	Anatomical Classification of the Angle-Closure Glaucomas . . .	96
6.4.1	Pupillary Block . . . . .	96
6.4.2	Plateau Iris . . . . .	99
6.4.3	Pseudoplateau Iris . . . . .	100
6.5	Lens-Related Angle-Closure . . . . .	100
6.6	Malignant Glaucoma . . . . .	102
6.7	Conclusion . . . . .	103
	References . . . . .	103

**CHAPTER 7**  
**Childhood Glaucoma and Amblyopia**  
**KARIM F. TOMEY**

7.1	Introduction . . . . .	105
7.2	Patient Evaluation . . . . .	106
7.2.1	Clinical Features . . . . .	106
7.2.2	Examination Under Sedation . . . . .	106
7.2.3	Examination Under Anesthesia (EUA) . . . . .	107
7.2.4	Special Diagnostic Tests . . . . .	109
7.3	Medical Management . . . . .	109
7.3.1	Indications . . . . .	109
7.3.2	Efficacy and Safety . . . . .	109
7.4	Surgical Management . . . . .	110
7.4.1	Goniotomy . . . . .	110
7.4.2	Trabeculotomy . . . . .	111
7.4.3	Trabeculectomy . . . . .	113
7.4.4	Goniotomy versus Trabeculotomy versus Trabeculectomy versus Other Procedures . . . . .	115
7.4.5	Glaucoma Drainage Implants . . . . .	117
7.4.6	Cyclodestructive Procedures . . . . .	118
7.5	Postoperative Management . . . . .	119
7.5.1	Periodic Clinical Examination . . . . .	119
7.5.2	Management of Amblyopia . . . . .	119
7.5.3	Genetic Counseling . . . . .	121
7.6	Conclusions . . . . .	121
	References . . . . .	122

**CHAPTER 8**  
**What Have We Learned from the Major Glaucoma Clinical Trials?**  
**J.D. BRANDT, M.R. WILSON**

8.1	Introduction . . . . .	125
8.2	Advanced Glaucoma Intervention Study (AGIS) . . . . .	127

8.3	Collaborative Normal Tension Glaucoma Study (CNTGS) . . . . .	129
8.4	Collaborative Initial Glaucoma Treatment Study (CIGTS) . . . . .	130
8.5	Ocular Hypertension Treatment Study (OHTS) . . . . .	131
8.6	Early Manifest Glaucoma Trial (EMGT) . . . . .	135
8.7	Conclusions . . . . .	136
	References . . . . .	136

**CHAPTER 9**  
**The Concept of Target IOP at Various Stages of Glaucoma**  
**C. MIGDAL**

9.1	Introduction . . . . .	139
9.2	The Relationship Between IOP and the Risk of Visual Field Progression . . . . .	140
9.3	Target Pressures in Glaucoma Management . . . . .	140
9.4	Target Pressure . . . . .	140
9.5	Randomized Controlled Trials and Target IOPs . . . . .	143
	References . . . . .	145

**CHAPTER 10**  
**A Practical Approach to the Management of Normal Tension Glaucoma**  
**R. A. HITCHINGS**

10.1	Introduction . . . . .	147
10.1.1	Background . . . . .	147
10.1.2	Differential Diagnosis . . . . .	148
10.1.3	Investigation . . . . .	151
10.1.4	Investigation for the Purpose of Management . . . . .	152
10.1.5	Management . . . . .	153
	References . . . . .	155

**CHAPTER 11**  
**Pseudoexfoliation Glaucoma**  
**URSULA SCHLÖTZER-SCHREHARDT, GOTTFRIED O.H. NAUMANN**

11.1	Background . . . . .	157
------	----------------------	-----

11.2	Pathobiology of PEX Syndrome . . . .	158
11.2.1	Pathogenesis . . . . .	158
11.2.2	Pathogenetic Factors . . . . .	160
11.2.3	Pathogenetic Concept . . . . .	160
11.2.4	Etiology . . . . .	160
11.3	Clinical Diagnosis . . . . .	161
11.3.1	Manifest PEX Syndrome . . . . .	161
11.3.2	Masked PEX Syndrome . . . . .	163
11.3.3	Early Stages of PEX Syndrome . . . .	164
11.3.4	Asymmetry of Involvement . . . . .	164
11.3.5	Differential Diagnosis . . . . .	164
11.4	Open-Angle Glaucoma in PEX Syndrome . . . . .	165
11.4.1	Epidemiology . . . . .	165
11.4.2	Clinical Features . . . . .	165
11.4.3	Pathomechanisms of Glaucoma Development . . . . .	166
11.4.4	Acute Open-Angle Glaucoma . . . . .	170
11.5	Angle-Closure Glaucoma in PEX Syndrome . . . . .	170
11.6	Management . . . . .	171
11.6.1	Medical Therapy . . . . .	172
11.6.2	Laser Trabeculoplasty . . . . .	172
11.6.3	Filtration Surgery . . . . .	172
11.7	Summary and Perspectives . . . . .	173
	References . . . . .	174

## CHAPTER 12

**Pigment Dispersion Syndrome – Update 2003**

ROBERT RITCH

12.1	Introduction . . . . .	177
12.2	Clinical Findings . . . . .	177
12.2.1	Anterior Segment . . . . .	177
12.2.2	Posterior Segment . . . . .	179
12.3	Pathophysiology . . . . .	179
12.4	Developmental Abnormalities Underlying PDS . . . . .	181
12.4.1	Blinking . . . . .	182
12.4.2	Accommodation . . . . .	183
12.4.3	Exercise . . . . .	183
12.5	Clinical Correlations . . . . .	183
12.5.1	Heredity . . . . .	183
12.5.2	Gender . . . . .	183
12.5.3	Race . . . . .	184
12.5.4	Refractive Error . . . . .	184
12.5.5	Asymmetric Involvement . . . . .	184
12.6	Natural History . . . . .	184
12.6.1	Active Phase . . . . .	184

12.6.2	Regression Phase . . . . .	185
12.6.3	Conversion to Glaucoma . . . . .	185
12.6.4	Differential Diagnosis . . . . .	185
12.6.5	Treatment . . . . .	186
	References . . . . .	188

## CHAPTER 13

**Wound Modulation in Glaucoma Surgery**

HOLGER MIETZ

13.1	Introduction . . . . .	193
13.1.1	Basics . . . . .	193
13.1.2	Wound Healing Following Trabeculectomy . . . . .	193
13.1.3	Therapeutic Options . . . . .	194
13.2	Clinical Experience with the Described Substances . . . . .	196
13.2.1	Corticosteroids . . . . .	196
13.2.2	5-Fluorouracil . . . . .	197
13.2.3	Mitomycin . . . . .	199
13.2.4	Transforming Growth Factor- $\beta$ . . . .	205
13.2.5	Suramin . . . . .	206
13.2.6	Additional Substances . . . . .	206
13.3	Current Clinical Practice/ Recommendations . . . . .	206
13.4	Post-operative Intensified Care . . . .	207
	References . . . . .	207

## CHAPTER 14

**Non-penetrating vs Penetrating Surgery  
of Primary Open-Angle Glaucoma**

STEFANO A. GANDOLFI, LUCA CIMINO

14.1	Introduction . . . . .	209
14.1.1	Basics . . . . .	209
14.2	Non-penetrating vs Penetrating Procedures: Clinical Evaluation . . . .	211
14.2.1	Efficacy . . . . .	211
14.2.2	Safety . . . . .	212
14.2.3	Affordability . . . . .	213
14.3	Conclusions . . . . .	214
	References . . . . .	214

<b>Subject Index</b> . . . . .	217
--------------------------------	-----



<http://www.springer.com/978-3-540-40608-2>

Glaucoma

Grehn, F.; Stamper, R. (Eds.)

2004, XIV, 232 p., Hardcover

ISBN: 978-3-540-40608-2